Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis
Results of a phase 3 clinical trial show an experimental drug called tolebrutinib can delay disability in patients with non-relapsing secondary progressive multiple sclerosis.
Health News is provided as a service to Kenton Drug Co. site users by HealthDay. Kenton Drug Co. nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.